Minjiang Chen Lei Zhang Wei Zhong Ke Zheng Wei Ye Mengzhao Wang
10.3389/fimmu.2021.619147
Front Immunol
2021 May 10;12:619147.
thsd7a (thrombospondin type 1 domain-containing protein 7a) immune checkpoint inhibitors immune related adverse event membranous nephropathy non-small cell lung cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/34040602/
Antibodies, Monoclonal, Humanized / adverse effects Glomerulonephritis, Membranous / diagnosis Glomerulonephritis, Membranous / etiology Immune Checkpoint Inhibitors / adverse effects Lung Neoplasms / complications Lung Neoplasms / immunology Thrombospondins / immunology
Antibodies, Monoclonal, Humanized / adverse effects Glomerulonephritis, Membranous / diagnosis Glomerulonephritis, Membranous / etiology Immune Checkpoint Inhibitors / adverse effects Lung Neoplasms / complications Lung Neoplasms / immunology Thrombospondins / immunology Case Reports Research Support, Non-U.S. Gov't Aged Antibodies, Monoclonal, Humanized / therapeutic use Autoantibodies / immunology Biomarkers Carcinoma, Non-Small-Cell Lung / complications Carcinoma, Non-Small-Cell Lung / diagnosis Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / immunology Disease Susceptibility Fluorescent Antibody Technique Humans Immune Checkpoint Inhibitors / therapeutic use Immunohistochemistry Lung Neoplasms / diagnosis Lung Neoplasms / drug therapy Male Tomography, X-Ray Computed Antibodies, Monoclonal, Humanized Autoantibodies Biomarkers Immune Checkpoint Inhibitors THSD7A protein, human Thrombospondins tislelizumab
PMC8141750
34040602
Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
2021